These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293 [TBL] [Abstract][Full Text] [Related]
23. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514 [TBL] [Abstract][Full Text] [Related]
24. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255 [TBL] [Abstract][Full Text] [Related]
25. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Budczies J; Kazdal D; Allgäuer M; Christopoulos P; Rempel E; Pfarr N; Weichert W; Fröhling S; Thomas M; Peters S; Endris V; Schirmacher P; Stenzinger A Lung Cancer; 2020 Apr; 142():114-119. PubMed ID: 32143116 [TBL] [Abstract][Full Text] [Related]
26. Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma. Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798 [TBL] [Abstract][Full Text] [Related]
27. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421 [TBL] [Abstract][Full Text] [Related]
28. Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. Sun D; Xu M; Pan C; Tang H; Wang P; Wu D; Luo H Front Oncol; 2022; 12():972972. PubMed ID: 36425562 [TBL] [Abstract][Full Text] [Related]
29. TMBur: a distributable tumor mutation burden approach for whole genome sequencing. Titmuss E; Corbett RD; Davidson S; Abbasi S; Williamson LM; Pleasance ED; Shlien A; Renouf DJ; Jones SJM; Laskin J; Marra MA BMC Med Genomics; 2022 Sep; 15(1):190. PubMed ID: 36071521 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153 [TBL] [Abstract][Full Text] [Related]
31. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing. Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470 [TBL] [Abstract][Full Text] [Related]
32. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299 [TBL] [Abstract][Full Text] [Related]
33. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. Asmann YW; Parikh K; Bergsagel PL; Dong H; Adjei AA; Borad MJ; Mansfield AS NPJ Precis Oncol; 2021 Mar; 5(1):22. PubMed ID: 33742076 [TBL] [Abstract][Full Text] [Related]
34. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256 [TBL] [Abstract][Full Text] [Related]
35. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613 [TBL] [Abstract][Full Text] [Related]
36. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975 [TBL] [Abstract][Full Text] [Related]
37. Tumour mutational burden and survival with molecularly matched therapy. de Bortoli T; Benary M; Horak P; Lamping M; Stintzing S; Tinhofer I; Leyvraz S; Schäfer R; Klauschen F; Keller U; Stenzinger A; Fröhling S; Kurzrock R; Keilholz U; Rieke DT; Jelas I Eur J Cancer; 2023 Sep; 190():112925. PubMed ID: 37544709 [TBL] [Abstract][Full Text] [Related]
38. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors. Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727 [TBL] [Abstract][Full Text] [Related]
39. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639 [TBL] [Abstract][Full Text] [Related]
40. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]